Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.26 USD
-0.01 (-2.85%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.26 0.00 (-0.95%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Cara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 101 | 146 | 167 | 181 | 155 |
Receivables | 4 | 4 | 1 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 2 | 3 | 0 | 0 |
Other Current Assets | 8 | 16 | 3 | 12 | 9 |
Total Current Assets | 116 | 169 | 173 | 195 | 166 |
Net Property & Equipment | 3 | 0 | 1 | 1 | 1 |
Investments & Advances | 0 | 11 | 70 | 71 | 63 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 0 | 0 | 0 | 0 |
Total Assets | 126 | 182 | 247 | 271 | 233 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 22 | 16 | 17 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 22 |
Total Current Liabilities | 26 | 23 | 18 | 18 | 43 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 37 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 23 | 20 | 22 | 46 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 742 | 727 | 709 | 641 | 587 |
Retained Earnings | -685 | -566 | -481 | -392 | -401 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 57 | 159 | 228 | 249 | 187 |
Total Liabilities & Shareholder's Equity | 126 | 182 | 247 | 271 | 233 |
Total Common Equity | 57 | 159 | 228 | 249 | 187 |
Shares Outstanding | 54.40 | 53.70 | 53.40 | 49.80 | 40.00 |
Book Value Per Share | 1.05 | 2.96 | 4.26 | 5.00 | 4.67 |
Fiscal Year End for Cara Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 57 | 70 | 101 | 79 | 95 |
Receivables | 2 | 3 | 4 | 6 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 3 | 3 | 3 | 3 |
Other Current Assets | 4 | 6 | 8 | 13 | 15 |
Total Current Assets | 64 | 81 | 116 | 101 | 125 |
Net Property & Equipment | 3 | 4 | 3 | 1 | 0 |
Investments & Advances | 0 | 0 | 0 | 5 | 7 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 2 | 2 |
Total Assets | 73 | 90 | 126 | 115 | 134 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 0 | 0 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 14 | 15 | 26 | 22 | 24 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 14 | 15 | 26 | 23 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 40 | 37 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 61 | 60 | 69 | 30 | 25 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 747 | 745 | 742 | 738 | 734 |
Retained Earnings | -735 | -715 | -685 | -652 | -624 |
Other Equity | 0 | 0 | 0 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 30 | 57 | 86 | 109 |
Total Liabilities & Shareholder's Equity | 73 | 90 | 126 | 115 | 134 |
Total Common Equity | 12 | 30 | 57 | 86 | 109 |
Shares Outstanding | 54.60 | 54.60 | 54.40 | 54.00 | 53.90 |
Book Value Per Share | 0.21 | 0.55 | 1.05 | 1.59 | 2.02 |